53,839 Shares in Omnicell, Inc. $OMCL Acquired by Odyssean LLC

Odyssean LLC purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 53,839 shares of the company’s stock, valued at approximately $2,235,000.

Other large investors also recently bought and sold shares of the company. AQR Capital Management LLC raised its stake in shares of Omnicell by 42.1% during the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock valued at $627,000 after purchasing an additional 5,311 shares during the period. Empowered Funds LLC boosted its stake in shares of Omnicell by 14.3% in the first quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock valued at $348,000 after purchasing an additional 1,243 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Omnicell by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock valued at $4,337,000 after purchasing an additional 4,866 shares during the period. Jane Street Group LLC grew its holdings in Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after purchasing an additional 109,382 shares in the last quarter. Finally, Creative Planning increased its stake in Omnicell by 16.7% during the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock worth $276,000 after buying an additional 1,347 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

Analysts Set New Price Targets

OMCL has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Wells Fargo & Company dropped their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. KeyCorp reiterated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Finally, Piper Sandler restated an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Stock Down 1.3%

Shares of Omnicell stock opened at $34.37 on Friday. The business has a 50-day moving average price of $39.34 and a 200 day moving average price of $39.24. Omnicell, Inc. has a fifty-two week low of $29.06 and a fifty-two week high of $55.00. The firm has a market cap of $1.56 billion, a P/E ratio of 40.92, a P/E/G ratio of 0.87 and a beta of 0.97. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.